Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Electricity has always been central to how life works, from the firing of neurons to the beating of the heart, but new ...

Physicists are now using a tightly controlled laser and a cloud of ultracold atoms to imitate the behavior of electrons in solids, effectively building a quantum version of electronics out of light ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

Omeros Corporation today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic ...

Performances in N.Y.C. Advertisement Supported by A holiday album that cuts through seasonal glut, a late collaboration by Jim McNeely and Helmut Lachenmann’s string quartets are among the highlights.

Latest reports show that Omeros Corporation (NASDAQ:OMER) has closed a deal worth around $2.1 billion with drug giant Novo Nordisk for the zaltenibart, a phase 2 asset of the former, in development ...

Omeros Corporation (NASDAQ:OMER) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. Latest reports show that Omeros Corporation (NASDAQ:OMER) has closed a deal worth around $2.1 ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...